Hospital Del Mar
- Address
- lock Available on a paid plan
Oncology & Solid Tumors
The Hospital Del Mar conducts extensive research in cancer across multiple organ systems, aiming to test new targeted agents and combination regimens that improve survival and quality of life.
- Advanced non‑small cell lung cancer
- Metastatic breast cancer (including triple‑negative and HER2‑positive)
- Renal cell carcinoma
- Colorectal cancer
- Urothelial carcinoma
The program emphasizes precision medicine, biomarker‑driven enrollment, and supportive care strategies for patients with high‑risk solid tumours.
Infectious Diseases & Antimicrobial Research
A broad portfolio of trials addresses bacterial, viral and fungal infections, evaluating novel antimicrobials, vaccine approaches and diagnostic improvements.
- Nontuberculous mycobacterial lung disease (MAC)
- Gram‑negative bacteremia and sepsis
- Invasive candidiasis and candidemia
- COVID‑19 therapeutic studies
- Respiratory viral infections in immunocompromised hosts
Research integrates antimicrobial stewardship principles and rapid diagnostic techniques to reduce morbidity and resistance.
Cardiovascular & Metabolic Disorders
Clinical investigations target heart disease, hypertension and lipid disorders, focusing on therapies that lower event rates and manage chronic conditions.
- Acute myocardial infarction (STEMI/NSTEMI)
- Heart failure with reduced ejection fraction
- Atherosclerotic cardiovascular disease with elevated Lp(a)
- Resistant hypertension
- Hypercholesterolemia and LDL‑C lowering strategies
The site leverages advanced imaging and biomarker profiling to personalize cardiovascular risk reduction.
Neurology & Neurodegenerative Diseases
Trials in the neurological field explore disease‑modifying treatments and symptom control for progressive disorders such as ALS, multiple sclerosis and Alzheimer’s disease.
- Amyotrophic lateral sclerosis (ALS)
- Relapsing‑remitting multiple sclerosis
- Early Alzheimer’s disease
- Focal onset epilepsy
- Chronic neuropathic pain syndromes
Patient‑reported outcomes and functional assessments are central to evaluating therapeutic impact.
Transplantation & Immune‑Mediated Disorders
Research at Hospital Del Mar includes kidney transplantation and a range of autoimmune conditions, seeking to improve graft tolerance and control immune dysregulation.
- Kidney transplant recipients with antibody‑mediated rejection
- Highly sensitised transplant candidates
- Immune thrombocytopenia (ITP)
- Systemic lupus erythematosus (SLE)
- Autoimmune cytopenias (wAIHA, CAD, ITP)
The program combines novel immunosuppressive regimens with biomarker monitoring to enhance long‑term graft survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 36 therapeutic areas and 15 of 590 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 559 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 140 by active trials.
- 1AstraZeneca AB16active
lock +139 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB35trials
lock +76 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Del Mar
lock Showing 1 of 491 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 590 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 36 | Unknown | 2016-09-16 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.